Myriad Genetics (NASDAQ:MYGN) traded higher on Wednesday after Piper Sandler upgraded the cancer test developer to Overweight ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The ...

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more ...

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral to Overweight. As of March 4, 2025, the average one-year price target ...

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors ...

Myriad Genetics is down 21.1% since the beginning of the year, and at $10.65 per share, it is trading 62.8% below its 52-week high of $28.60 from September 2024.

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 ...